Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 235Precursor Cell Lymphoblastic Leukemia-Lymphoma 69Recurrence 36Burkitt Lymphoma 34Leukemia 32Lymphoma 30Neoplasms, Plasma Cell 22Lymphoma, Non-Hodgkin 19Immunoglobulin Light-chain Amyloidosis 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Mantle-Cell 16Neoplasms 15Nausea 15Lymphoma, Large B-Cell, Diffuse 15Vomiting 14Hodgkin Disease 13Breast Neoplasms 12Waldenstrom Macroglobulinemia 11Leukemia, Biphenotypic, Acute 11Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Amyloidosis 10Lung Neoplasms 9Smoldering Multiple Myeloma 8Prostatic Neoplasms 8Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Hematologic Neoplasms 7Blast Crisis 7Lymphoma, T-Cell, Cutaneous 6

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Proteostasis Deficiencies × Calcium Dobesilate × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡